Point of Care (POC) diagnostics for microbial infections and POC susceptibility measurements: The need in Indian context. Dr.

Similar documents
Rapid Diagnostics CHAI Experience. 6 th Moving Forward in Diagnostics Forum Les Pensieres November 7, 2012

IP Lab Webinar 8/23/2012

New Generation of Nucleic Acid Testing. Michele Owen, Ph.D Division of HIV/AIDS Prevention Centers for Disease Control & Prevention

The Three Millennium Development Goal Fund A guide for the selection of Malaria Rapid Diagnostic Test kits purchased with 3MDG grants

WHO public announcement to rapid diagnostic test manufacturers, procurement agencies and national malaria control programmes

The Role of POCT in Management of Infectious Disease in the Critical Care Setting

ESPnet: An Overview of Electronic Case Reporting using EHRs

Rapid Point-of-Care Tests for STIs: needs, progress, challenges

East Africa Regional CD4 Workshop: The Role of CD4 Testing During Viral Load Scale-Up

Innovations in nucleic acid amplification technologies. Automated platforms for NAT. Microfluidics Digital PCR Innovations in nucleic acid microarrays

POSITIONING OF TB DX : TIERED SYSTEM, INTEGRATED APPROACH

How best to structure a laboratory network with new technologies

WHO recommendations. Diagnostic testing in infants

CONSIDERATIONS IN UTI DETECTION AND POTENTIAL IMPACT ON ANTIBIOTIC STEWARDSHIP

Consolidated Donor Funded Procurement of HIV Diagnostics

HIV Infection in Pregnancy. Francis J. Ndowa WHO RHR/STI

An STBBI Testing Update and the Quest for the 300

OraSure Technologies. JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE June 4, 2014

COMMUNICABLE DISEASE REPORT Quarterly Report

point-of-care test (POCT) Definition: an analytical or diagnostic test undertaken in a setting distinct from a normal hospital or non-hospital

CD4 Assays Are No Longer Needed for Care of Children in Low-resource Countries. The case against Di Gibb

WHO Guidelines on hepatitis B and C testing

Laboratory Services and Networks Your priorities?

Chain of Infection Agent Mode of transmission Contact (direct, indirect, droplet spread) Airborne Common-vehicle spread Host

CD4 WORKSHOP REPORT JULY 22, 2017

Balancing investment in point of care diagnostics versus laboratory testing in low resource settings. June 28, 2011

Anti-Infective Clinical Trials

The Application of molecular POCT for Influenza and Group A Strep Detection

Pathology the missing link in global health care delivery Quentin Eichbaum

Current and Emerging Legionella Diagnostics

Haemophilus influenzae and its invisibility cloak. Anna Strain Virology Supervisor/VPD Reference Center Coordinator June 5, 2018

SP.718 Special Topics at Edgerton Center: D-Lab Health: Medical Technologies for the Developing World

Opportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests

POC EID Implementation Models, Linkage to Care & Operational Challenges

The Global Fund s role as a strategic and responsible investor in HIV/AIDS: Paediatrics and PMTCT

MEETING THE STANDARDS: FDA MANDATORY RAPID INFLUENZA DETECTION TEST (RIDTs) RECLASSIFICATION

Lahey Clinic Internal Medicine Residency Program: Curriculum for Infectious Disease

SIMPLIFYING DIAGNOSTICS IMPROVING GLOBAL HEALTH

Robert G. Gish MD UC San Diego

Diagnostics: Bench to Bedside Pathway

Vision and strategies to Increase Access to Innovative HIV Diagnostic Technologies. Willy Urassa. AMD STAKE HOLDERS MEETING 7-8 May 2013

HUMASIS MALARIA ANTIGEN TEST HIGH SENSITIVE DIFFERENTIAL DIAGNOSIS OF MALARIA INFECTION

HIV Basics: Clinical Tests and Guidelines

Table of Contents (continued)

MP Biomedicals Asia Pacific Pte. Ltd. (formerly Genelabs Diagnostics Pte. Ltd.)

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Elizabeth C. Dee, 1,2 Noelle Cocoros, 1 Liisa M. Randall, 2 Hannah Rettler, 2 Mark Josephson, 3 Michael Klompas 1,4

Forward Looking Statements

7 th FIDSSA CONFERENCE 2017 Programme as at 11 May 2017 PROVISIONAL ACADEMIC PROGRAMME

HIV Update in Laboratory Testing. Patricia Slev, PhD, D(ABCC)

CULTURE OR PCR WHAT IS

HIV Testing. Susan Tusher, LMSW Program Coordinator The Kansas AIDS Education and Training Center

WHO Prequalification of In Vitro Diagnostics Programme

How has the Polio Eradication Initiative influenced the global AIDS response? Bradley S. Hersh, MD, MPH

To provide you with the basic concepts of HIV prevention using HIV rapid tests combined with counselling.

IHI Biomedical Sciences Group. Joseph Mugasa, PhD, PD. Stakeholders Meeting

Advanced HIV and seriously ill: challenges in low resource settings Rosie Burton, Southern African Medical Unit, MSF

The population impacts of ART scale-up in rural KwaZulu-Natal, South Africa: Findings from the Africa Centre s population cohort

SIXTY-SEVENTH WORLD HEALTH ASSEMBLY A67/13 Provisional agenda item March Hepatitis

Safety Data Sheet Product Name: Heparin / PF4 Serum Panel - For In Vitro Diagnostic Use Only

HIV AND LUNG HEALTH. Stephen Aston Infectious Diseases SpR Royal Liverpool University Hospital

Classification of Infectious Disease Law in Japan

How are testing technologies used to diagnose HIV infection?

Alere Technologies GmbH

targets for HIV-positive children

Centers for Disease Control and Prevention (CDC) FY 2009 Budget Request Summary

CHAPTER ONE: EXECUTIVE SUMMARY

2012 California Clinical Laboratory Survey: STD/HIV/Hepatitis Testing

Microchip Technology. Xuanhong Cheng Materials Science and Engineering

WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: OraQuick HIV 1/2 Rapid Antibody Test WHO reference number: PQDx

Communicable Disease. Introduction

WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: OraQuick HIV 1/2 Rapid Antibody Test WHO reference number: PQDx

Molecular diagnosis of infectious disease - Method validation and environmental setting 傳染病的分子診斷 - 方法確認與環境背景. WC Yam 任永昌

R&D AND INNOVATION. Francesco Colotta Senior Corporate VP and Chief Medical Officer

Tying it all together health economic modeling

Annex 13. Indicators for HIV testing services reference sheet

Update on WHO Prequalification of IVDs

AdvaMedDx Value Assessment Framework in Practice

On behalf of the Infectious Diseases Society of America (IDSA), I offer testimony in

Structure and duties of Blood service

Coding for Preventive Services A Guide for HIV Providers

Program to control HIV/AIDS

Module 3: Overview of HIV Testing Technologies

Antimicrobial resistance Fact sheet N 194 Updated April 2014

AREAS OF CONCENTRATION

Microbiology EQA Product Portfolio

43. Guidelines on Needle stick Injury

Press Release. Date: 24 March Re: Launch of the Online TB Surveillance Dashboard

PCR Is Not Always the Answer

Alere Triage Meterpro Alere

ORYX Translational Medicine. Dr. Bernard Huber/ CEO

Role of subclinical TB: Can we model prevention of TB in the subclinical stages?

Diagnostics RDT / POC Technology for ZIKA related infections

TUBERCULOSIS AND HIV/AIDS: A STRATEGY FOR THE CONTROL OF A DUAL EPIDEMIC IN THE WHO AFRICAN REGION. Report of the Regional Director.

Use of a Multidisciplinary Care Model for Pregnant Women Living with HIV & Their Infants Sarah McBeth, MD MPH

DNA amplification and detection using a ph-sensing system:

ICAP Journal Club. Article. Study Summary

Action Item for 2019 Review of Tool. Maintain (add include oral cavity) Maintain. Archive. Archive. 12 creatinine)

Impact of POC EID on infant case finding and treatment initiation. Durban, South Africa June

The population impacts of ART scale-up in rural KwaZulu-Natal, South Africa: Results from the Africa Centre s population cohort

Transcription:

Point of Care (POC) diagnostics for microbial infections and POC susceptibility measurements: The need in Indian context Dr. Ramesh Paranjape

Definition of POC a medical test that is conducted at or near the site of patient care. any test that is performed at the time at which the test result enables a clinical decision to be made and an action taken that leads to an improved health outcome. a diagnostic test that is performed near the patient or treatment facility, has a fast turnaround time, and may lead to a change in patient management

Blood Glucose 1962 Rapid Pregnancy Tests 1977 Early 90s Electrolytes Over 100 companies marketting POC kits for various purposes

Applications in resource-replete emergency departments or intensive care units In out patient clinics or mobile testing units

POC Tests Hospital/facility based The goal of point-of-care testing is to obtain immediate test results to help guide an emergent intervention. Emergency Depts/ICUs Blood group cross-matching Measurement of electrolytes Treatment of Sepsis Ante-natal clinics Field Based The goal of point-of-care testing is to expedite diagnostic testing without the need for services of a remote clinical laboratory to accelerate treatment initiation, triage patients appropriately, and improve health outcomes. Surveillance Monitoring of health Blood glucose Pregnancy Diagnosis of Infectious diseases HIV, TB, Malaria

Hospital/Facility based MATRIX-ASSISTED LASER DESORPTION/IONIZATION TIME-OF- FLIGHT MASS SPECTROMETRY (MALDI-TOF MS) FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING FLEXICULT SSI-URINARY KIT FOR URINARY TRACT INFECTION DIAGNOSIS AND SUSCEPTIBILITY TESTING BIOFIRE FILM ARRAY RESPIRATORY PANEL (RP) FOR THE DETECTION OF BACTERIAL AND VIRAL PATHOGENS. BREATH TESTS FOR THE DIAGNOSIS OF INFECTIOUS DISEASES Field based BIOSENSOR PLATFORM FOR RAPID ANTIMICROBIAL SUSCEPTIBILITY TESTING LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) PCR

Need for POC in Indian Settings Tuberculosis: Diagnosis and Susceptibility HIV: Susceptibility and Virus load Flaviviruses: Diagnosis Malaria: Diagnosis and Susceptibility Respiratory Infections Sexually transmitted infections Sepsis

Laboratory independent diagnostic tests for just four infections (bacterial pneumonia, syphilis, malaria, and tuberculosis) could prevent more than 1 2 million deaths each year in developing countries

Way forward to Achieve 90-90-90 objectives of UNAIDS by 2020 HIV Infected Persons Self testing, Home based testing Diagnosed to be HIV +ve POC (CD4 counts) (90%) Put on Treatment POC (Virus Load) (90%) Virally Suppressed (90%)

Evaluation of HIV serology POCs: NARI experience The rapid tests being extensively used for HIV diagnosis for the last 15 years are example of POCT for HIV diagnosis New POCs: test on oral fluid Three different rapid kits evaluated (Calypte Aware HIV1 /2, OraQuick Rapid HIV1/2, Oracheck HIV) Qualitative in vitro immunoassay for the detection of antibodies to All three kits showed good sensitivity, specificity and PPV Results were clear and easy to interpret 95 % respondents were willing to give oral sample as it is less invasive than venepuncture sample The healthcare staff felt that the sample collection has less bio-safety hazard

Evaluation of CD4 POCs: NARI experience POCs evaluated: BD FACSPresto and PIMA Alere CD4 analyzer Multisite study More than 700 samples Range of CD4 counts (50 to >1000 cells/mm3) Minimum error rate: <5% Field based analysis of PIMA: Inter-machine comparison : %CV<10%. 91% requiring ART were correctly identified

Bigtec Labs has developed a handheld diagnostic platform for rapid pathogen detection of any disease and allows DNA amplification. Currently, the company is validating the product specifically for hepatitis B, C and HIN1 where with a single drop of blood the diagnosis can be made within minutes Our battery operated, real-time micro-pcr is poised to revolutionize medical analysis and treatment infield, and in the laboratory, by reducing the analysis time and driving down the cost of medical diagnostics by orders of magnitude, claims Chandrasekhar Nair, director of Bigtec Labs.

Effect of point-of-care CD4 cell count results on linkage to care and antiretroviral initiation during a home-based HIV testing campaign: a non-blinded, clusterrandomised trial Mitesh A Desai et al Lancet HIV 2017 http://dx.doi.org/10.1016/ S2352-3018(17)30091-7 A two-arm, cluster-randomised, controlled efficacy trial in two districts of western Kenya. with ongoing HBCT. Housing compounds were randomly assigned (1:1) to point-of-care CD4 cell counts (366 compounds with 417 participants) or standard-of-care (318 compounds with 353 participants) CD4 cell counts participants in the point-of-care group, 215 (58%) had linked to care within 6 months versus 108 (34%) of 321 in the standard-of-care group

TB Diagnosis

Name Manufacturer Species Dx Paracheck-Pf Orchid Biomedical Systems Antigen Stability Pf PfHRP-2 4-40 Rapid Malaria Pf/Pv Accu-tel Pf & Pv PfHRP-2 and P.vivax pldh ParaHIT-F Parabank Malascan Indian POCs for Malaria Diagnosis (Span Diagnostics Ltd Zephyr Biomedicals Zephyr Biomedicals 2-30 Pf PfHRP-2 4-40 Panspecific Pf & Panspecific Pan-pLDH 4-30 PfHRP2 and aldolase 4-30 Parascreen Zephyr Biomedicals Pf or non- Pf mixed PfHRP2 and pldh 4-30 First Response Malaria (pldh/hrp2combo test) Premier Medical Corporation Pf or non- Pf mixed PfHRP-2 and panpldh 1-40

Challenges 1.Lower sensitivity compared to laboratory based assays 2.Issues related to Quality Assurance: Internal controls, external controls, documentation, EQAS 3.Usually higher cost (Eg GenExpert) 4.Lack of regulatory standards for approval of diagnostics; 5.Validation and field testing 6.Variable quality of laboratory services; Training & interpretation (esp for self tests)